Creative Biolabs

Currently, CAR-T therapy using ex vivo-generated cells poses multiple barriers associated, being complicated and expensive to manufacture, and with a high risk of toxicity. Therefore, in vivo CAR-T Cell Engineering is a potential solution with the ease of production and the possibility of standardization. Furthermore, studies have shown that in vivo CAR-T Engineering is associated with a reduced risk of the most common toxicities, such as CRS, and "on-target, off-tumor" toxicity.